Coya Therapeutics announced that the U.S. Food and Drug Administration (FDA) granted fast track designation to COYA 302, a novel biologic combination therapy. The company is currently investigating COYA 302 as a potential treatment for amyotrophic lateral sclerosis (ALS).

The FDA’s fast track designation is intended to expedite the development and review of new drugs and biologics that treat serious conditions and fill an unmet medical need. This designation allows for more frequent meetings and communication with the FDA during the drug development process, as well as the potential for accelerated approval and priority review if relevant criteria are met.

Source: GO-AI-ne1